 |
|
Weight gain induced by antipsychotic drugs can be avoided
January 17, 2008A research team from Université Laval's Faculty of Medicine and Robert-Giffard Hospital has demonstrated that weight gain induced by the use of antipsychotic drugs-which in extreme cases can be as high as 30 kilos in only one month-can be avoided through a specially designed weight control program. The researchers supervised by psychiatrist Marie-Josée Poulin and kinesiologist Angelo Tremblay report the details of their findings in a recent edition of the Australian and New Zealand Journal of Psychiatry.
The researchers tested their weight control program's effectiveness on a group of 59 patients treated for mental health problems. These people, suffering from schizophrenia and psycho-affective or bipolar disorders, had been using antipsychotic drugs for almost three years on average.
Patients were invited to attend a 90-minute educational session about healthy eating and physical activity. They then took part in two one-hour workout sessions every week for an 18-month period. These workouts included both aerobic and muscle-building exercises and were supervised by kinesiologists.
To evaluate the program's effectiveness, the research team regularly measured the participants' key biochemical and physical parameters and compared them to those of a control group made up of 51 sedentary or moderately active patients also taking antipsychotic medication.
In the control group, subjects' weight, waist size and body mass index increased on average more than 4% from the beginning to the end of the study. Their levels of bad cholesterol and triglycerides also went up 15% and 12% respectively.
In contrast, the subjects who took part in the weight control program saw their average weight, waist size and body mass index decrease by 4% or more while their levels of good cholesterol went up 21%, their bad cholesterol went down 14%, and their triglycerides levels decreased by 26%.
"This is encouraging news for people suffering from mental illness because weight gain induced by antipsychotic drugs has several negative effects: it disrupts the lipid profile, increases cardiovascular and diabetes risk, and interferes with effective treatment follow-up," points out Jean-Philippe Chaput, co-author of the study. "Our results highlight the importance of a weight control program designed specifically for people who take antipsychotic drugs. In an ideal world, every prescription for antipsychotic medication should be accompanied by a prescription for physical training," concludes the researcher.
Université Laval
To evaluate the program's effectiveness, the research team regularly measured the participants' key biochemical and physical parameters and compared them to those of a control group made up of 51 sedentary or moderately active patients also taking antipsychotic medication.
In the control group, subjects' weight, waist size and body mass index increased on average more than 4% from the beginning to the end of the study. Their levels of bad cholesterol and triglycerides also went up 15% and 12% respectively.
In contrast, the subjects who took part in the weight control program saw their average weight, waist size and body mass index decrease by 4% or more while their levels of good cholesterol went up 21%, their bad cholesterol went down 14%, and their triglycerides levels decreased by 26%.
"This is encouraging news for people suffering from mental illness because weight gain induced by antipsychotic drugs has several negative effects: it disrupts the lipid profile, increases cardiovascular and diabetes risk, and interferes with effective treatment follow-up," points out Jean-Philippe Chaput, co-author of the study. "Our results highlight the importance of a weight control program designed specifically for people who take antipsychotic drugs. In an ideal world, every prescription for antipsychotic medication should be accompanied by a prescription for physical training," concludes the researcher.
Université Laval
Antipsychotic Current Events and Antipsychotic News RSSThe future of schizophrenia
Schizophrenia is a major public health problem. Affecting almost 1% of the world's population, it takes an enormous economic and social toll in addition to the distress, dysfunction, disability and mortality for those afflicted with this disease.
Anti-psychotic drugs could help fight cancer
The observation that people taking medication for schizophrenia have lower cancer rates than other people has prompted new research revealing that anti-psychotic drugs could help treat some major cancers.
Traffic jam in brain causes schizophrenia symptoms
Schizophrenia waits silently until a seemingly normal child becomes a teenager or young adult. Then it swoops down and derails a young life.
Map of your brain may reveal early mental illness
John Csernansky wants to take your measurements. Not the circumference of your chest, waist and hips. No, this doctor wants to stretch a tape measure around your hippocampus, thalamus and prefrontal cortex.
Early and network-oriented care may help adolescents at risk of developing psychosis
Family and network oriented, stress-reducing care improves level of overall functioning and mental health in adolescents at risk of developing psychosis, suggests a recent Finnish study.
Flow of potassium into cells implicated in schizophrenia
A study on schizophrenia has implicated machinery that maintains the flow of potassium in cells and revealed a potential molecular target for new treatments.
Researchers discover link between schizophrenia and diabetes
People with schizophrenia are at increased risk for type 2 diabetes, Medical College of Georgia researchers have found.
Combating weight gain caused by antipsychotic treatments
Antipsychotic drugs, such as olanzapine (Zyprexa), risperidone (Risperdal) and quetiapine (Seroquel), are commonly used to treat psychotic disorders like schizophrenia, but also bipolar disorder and even behavioral problems related to dementia.
Innappropriate drug prescriptions wasting millions, raising health risks
A recent study in Oregon suggests that drugs designed for treating the most severe mental illnesses are often prescribed at inappropriately low doses and at considerable expense, for use in conditions where their benefit has not been established.
Bipolar disorder linked to risk of early death from natural causes
Bipolar disorder appears to increase the risk of early death from medical illnesses, according to a literature review study published as the lead article this week in the journal Psychiatric Services.
More Antipsychotic Current Events and Antipsychotic News Articles
 |
Stahl's Illustrated Antipsychotics by Stephen M. Stahl (Author) All of the titles in the Stahl's Illustrated Series are designed to be fun. Concepts are illustrated by full-color images that will be familiar to all readers of Stahl's Essential Psychopharmacology, Third Edition and The Prescriber's Guide. The texts in this user-friendly series can be supplements to figures, images, and tables. The visual learner will find that these books make psychopharmacology concepts easy to master, while the non-visual learner will enjoy a shortened text version of complex psychopharmacology concepts. Within each book, each chapter builds on previous chapters, synthesizing information from basic biology and diagnostics to building treatment plans and dealing with complications and comorbidities. Novices may want to approach Stahl's Illustrated Series by first... |
 |
Higher or Lower: Dosing Issues in the Use of Atypical Antipsychotics In spite of the great deal of clinical and basic research, the dosing strategies for atypical antipsychotics still lack a firm rational basis. The manufacturers of atypical antipsychotics recommend ranges (in mg/day) within which the products are supposed to be safe and effective. The selection of the individual patients dose within (or outside) these ranges is up to clinical judgment that should, theoretically, strike the optimal balance between the therapeutic and adverse effects. In practical terms, clinical judgment is difficult to define, and quality is hard to assess. This program will review the dosing and plasma levels of the atypical antipsychotics. |
 |
The Effects Of Anti-Psychotic Medication Forced Upon The Unfortunate Souls Who May Or May Not Need T Lafcadio (Primary Contributor) |
 |
Promoting Wellness: Schizophrenia (Online Tutorial for Institutions) by Adrianne Avillion and Mary Dreher, Educational Global Technologies, Inc. The goal of the online tutorial Promoting Wellness: Schizophrenia is to help healthcare professionals recognize this disorder and its impact on clients, families, and the community, and to promote treatment strategies that enhance the health and wellness of clients dealing with this disorder. This online tutorial is approved for continuing education. |
 |
Essential Psychopharmacology of Antipsychotics and Mood Stabilizers (Essential Psychopharmacology Series) by Stephen M. Stahl (Author), Nancy Munter (Illustrator) Drawn from the best-selling second edition of Essential Psychopharmacology, Steve Stahl has revised and updated the chapters covering antipsychotics and mood stabilizers in this separate volume. This new book covers the many dimensions of psychosis, particularly as associated with schizophrenia, and examines the role of dopamine in psychosis along with the various theories about the causes, pathophysiology, and treatment of schizophrenia. New material includes discussion of a promising new agent, aripiprazole, the first in a new class of dopamine stabilizers; the use of anticonvulsant agents to treat manic psychosis as well as being used as adjuncts to more traditional antipsychotic treatments for psychosis and schizophrenia; and the newest atypical antipsychotic ziprasidone. CME... |
 |
Antipsychotics and Mood Stabilizers: Stahl's Essential Psychopharmacology, 3rd edition (Essential Psychopharmacology Series) by Stephen M. Stahl (Author) Relying upon the best-selling third edition of Stahl's Essential Psychopharmacology, Dr. Stephen M. Stahl has revised chapters covering antipsychotics and mood stabilizers for this third edition of Antipsychotics and Mood Stabilizers. More than one-third longer than the previous edition, Antipsychotics and Mood Stabilizers is essential reading for professionals treating psychosis and students learning the mechanisms of drug reactions. This updated edition includes advances in neurobiology and recent clinical developments to explain the concepts underlying drug treatment of psychiatric disorders. The fully revised text is complemented by many new illustrations and enhanced to reflect new knowledge and topics not covered in the previous edition. Intended as a primer text covering all... |
 |
Psychopharmacology of Antipsychotics by Stephen M. Stahl (Author) (Martin Dunitz) Univ. of California, San Diego. Pocket-sized text presents a series of visual lessons on the antipsychotic drugs. Figures and diagrams are based on the textbook Essential Psychopharmacology, c1996. Color illustrations. For clinicians and students. Trim size: 8.25 x 5.75 inches. Softcover. |
 |
Medicines for Mental Health: The Ultimate Guide to Psychiatric Medication by Kevin Thompson PhD (Author) A finalist in the National Indie Excellence 2008 book awards, this book was written for anyone who suffers from sexual dysfunction, depression, bipolar disorder, or schizophrenia (or cares for someone who does). Medicines for Mental Health is the first book to provide detailed and readable information about all psychiatric medications, and other medical treatments, for these mental illnesses. Medicines cuts through jargon, demystifies mental illness, and explains how treatments work. It goes beyond current fads to cover important medications you need to know about, including many that will be new to your doctor. |
 |
Tarascon Rapid Reference Card: Antipsychotics and Anxiolytics by Dr.Joseph Esherick (Author), MD (Author) Measuring only 5.5 x 3.25 inches, this quick and handy laminated card tucks neatly into your Tarascon books to provide you with immediate access to the most frequently used tables in your Tarascon Pharmacopoeia or Pocketbook. |
 |
The Prescriber's Guide, Antipsychotics and Mood Stabilizers (Shahl's Essential Psychopharmacology) by Stephen M. Stahl (Author) In response to rapid developments in psychopharmacology, this is a spin-off from Stephen M. Stahl's new, completely revised and updated third edition of his much-acclaimed Prescriber's Guide. It covers the most important drugs in use today for psychosis and mood stabilization. In full color throughout, and with four or more pages for each of the antipsychotic drugs, Stephen M. Stahl distills his great expertise into a pragmatic formulary that gives all the information a prescriber needs to treat patients effectively. Each drug is covered in five categories: general therapeutics, dosing and use, side effects, special populations, and pearls. Target icons appear next to key categories for each drug so that the prescriber can go easily and instantly to the information needed. Several... |
| © 2009 BrightSurf.com |